Kim, Dasom Min, Dongwha Kim, Joohee Kim, Min Jung Seo, Yerim Jung, Byung Hwa Kwon, Seung-Hae Ro, Hyunju Lee, Seoee Sa, Jason K. Lee, Ji-Yun 2024-01-19T08:02:14Z 2024-01-19T08:02:14Z 2024-01-04 2023-12 0392-9078 https://pubs.kist.re.kr/handle/201004/113008 Background Oncogenic KRAS mutation, the most frequent mutation in non-small cell lung cancer (NSCLC), is an aggressiveness risk factor and leads to the metabolic reprogramming of cancer cells by promoting glucose, glutamine, and fatty acid absorption and glycolysis. Lately, sotorasib was approved by the FDA as a first-in-class KRAS-G12C inhibitor. However, sotorasib still has a derivative barrier, which is not effective for other KRAS mutation types, except for G12C. Additionally, resistance to sotorasib is likely to develop, demanding the need for alternative therapeutic strategies.Methods KRAS mutant, and wildtype NSCLC cells were used in vitro cell analyses. Cell viability, proliferation, and death were measured by MTT, cell counting, colony analyses, and annexin V staining for FACS. Cell tracker dyes were used to investigate cell morphology, which was examined by holotomograpy, and confocal microscopes. RNA sequencing was performed to identify key target molecule or pathway, which was confirmed by qRT-PCR, western blotting, and metabolite analyses by UHPLC-MS/MS. Zebrafish and mouse xenograft model were used for in vivo analysis.Results In this study, we found that nutlin-3a, an MDM2 antagonist, inhibited the KRAS-PI3K/Akt-mTOR pathway and disrupted the fusion of both autophagosomes and macropinosomes with lysosomes. This further elucidated non-apoptotic and catastrophic macropinocytosis associated methuosis-like cell death, which was found to be dependent on GFPT2 of the hexosamine biosynthetic pathway, specifically in KRAS mutant /p53 wild type NSCLC cells.Conclusion These results indicate the potential of nutlin-3a as an alternative agent for treating KRAS mutant/p53 wild type NSCLC cells. English BioMed Central Nutlin-3a induces KRAS mutant/p53 wild type lung cancer specific methuosis-like cell death that is dependent on GFPT2 Article 10.1186/s13046-023-02922-8 1 Journal of Experimental and Clinical Cancer Research, v.42, no.1 Journal of Experimental and Clinical Cancer Research 42 1 Y scie scopus 001126305900001 2-s2.0-85179768015 Oncology Oncology Article ONCOGENIC RAS ACTIVATION PATHWAY P53 MACROPINOCYTOSIS PHOSPHORYLATION ANTAGONISTS INHIBITOR INDUCTION ATPASE KRAS mutation GFPT2 HBP Macropinocytosis Nutlin-3a Methuosis